The Broker Innovation Lab celebrates brokers and other benefits stakeholders who have embraced the changing marketplace to position themselves and their business for future success
The lawsuit alleged a years-long insulin pricing scheme that artificially inflated the price of lifesaving diabetes medications and deceived consumers about those inflated prices.
To afford insurance at all, people may opt for a plan with low premium payments but with a high deductible, gambling that they won’t have any medical crises.
To afford insurance at all, people may opt for a plan with low premium payments but with a high deductible, gambling that they won’t have any medical crises.
The American Hospital Association and Maine Hospital Association on Monday filed a lawsuit in U.S. District Court in Maine to stop upcoming changes to the federal 340B Drug Pricing Program.
Judge Quraishi ruled that the connection between premiums paid by plan participants and out-of-pocket costs and the administrative fees the plans paid to their pharmacy benefit manager was “speculative.”
The U.S. government alleged that CVS improperly requested and received GHP reimbursement for premature refills, dispensed excessive insulin pens, and falsely under-reported the days-of-supply of insulin that its pharmacies dispensed.
The plan to eventually phase out rebates more broadly portends a seismic shift in the flow of billions of dollars among drugmakers, insurers and employers.